Ryan Watts, Denali CEO

Bio­gen hands De­nali $1B-plus in cash, $1B-plus in mile­stones to part­ner on late-stage Parkin­son’s drug

Bio­gen is hand­ing over more than a bil­lion dol­lars cash to part­ner with the up-and-com­ing neu­ro­sciences crew at De­nali on a new ther­a­py for Parkin­son’s. And the big biotech is ready to pile on more than a bil­lion dol­lars more in mile­stones — if the al­liance is a suc­cess.

For Bio­gen $BI­IB, the move on De­nali’s small mol­e­cule in­hibitors of LRRK2 puts them in line to col­lab­o­rate on a late-stage pro­gram for DNL151, which is sched­uled to start next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.